For example, Pembrolizumab, a type of anti‐PD‐1 immunotherapy drug, is recommended for treating advanced patients without a mutation in EGFR and anaplastic lymphoma kinase (ALK) and with high PD‐L1 expression.1 But for NSCLC at least, while durable responses have been observed in some patients, checkpoint inhibition does not have the same effect for all the patients.7 Additional biomarkers besides PD‐L1 expression are needed to achieve improved efficacy of immunotherapies. Here, ALK is linked to non-small cell lung carcinoma.